Avicanna Applauds President Trump's Executive Order to Reclassify Cannabis & Provides Scientific Update

Executive Summary

• Avicanna highlights progress in clinical development, R&D, and medical affairs for 2025, including a real‑world evidence study with ~450 patients and the start of its first Phase II trial for arthritic pain.
• The company received a new USPTO patent and advanced its proprietary drug‑delivery platform (PwdRx™) toward commercial deployment.
• Avicanna welcomes President Trump’s executive order reclassifying cannabis to Schedule III, citing expected benefits for research, investment, and patient access.

Key Details

• Regulatory Environment: President Trump issued an executive order moving cannabis from Schedule I to Schedule III, which Avicanna says could facilitate further clinical research, innovation, and reimbursement pathways.
• Clinical Development:
• Real‑world evidence study with University Health Network (UHN) has enrolled ~450 patients to assess pain, sleep, anxiety, and depression outcomes.
• First Phase II randomized controlled trial for arthritic pain using Avicanna’s proprietary cannabinoid formulation commenced in December 2025.
• R&D Advancements:
• New USPTO patent granted (details not disclosed).
• Translation of additional proprietary products/technologies, including the PwdRx™ drug‑delivery system, from lab to commercial stage.
• Ongoing optimization of the Rho Phyto™ medical cannabis portfolio.
• Medical Affairs:
• Expanded educational events, symposiums, and Avicenna Academy initiatives.
• Enhancements to MyMedi.ca platform, patient support programs, clinical guidance resources, and insurance reimbursement initiatives.
• Product Portfolio Highlights:
• Rho Phyto™ formulary now offers oral, sublingual, topical, and transdermal cannabinoid products across Canada with plans for international expansion.
• MyMedi.ca care platform provides bilingual pharmacist‑led support, specialty services for veterans, and payer collaboration for reimbursement.
• Leadership Quote: CEO Aras Azadian emphasized the importance of evidence‑based approaches and expressed optimism that the regulatory change will accelerate research, investment, and patient access to cannabinoid therapies.

Notable Quotes

“As a biopharmaceutical company focused on cannabinoid‑based medicines, this development represents an important milestone… We believe this regulatory direction may facilitate further clinical research, support innovation, and encourage investment into the development of rigorously validated cannabinoid‑based therapies…” – Aras Azadian, CEO, Avicanna Inc.